Calciphylaxis of the penis and distal digits: a case report

Gordon Smilnak1, Michael Jiang2,3 and Bijal Jain2,3*

Abstract

Background: Calciphylaxis is a rare, often fatal disease resulting from calcification of dermal arterioles and capillaries. Usually diagnosed in patients with end-stage renal disease, this disorder typically presents as necrotic, nonhealing ulcers in acral or adipose areas. Here we report the case of an elderly man who was found to have calciphylaxis of the distal digits and penis, the latter of which is an uncommon site of disease that carries a particularly poor prognosis.

Case presentation: A 73-year-old African American man with multiple medical comorbidities including dialysis-dependent end-stage renal disease presented with worsening painful, necrotic lesions on his glans penis and several distal digits over the last 2 months. The wound on the glans was foul smelling with overlying purulence and had been unsuccessfully treated with amoxicillin–clavulanic acid. Discovery of diffuse intravascular calcification on computed tomography, in addition to a markedly elevated calcium–phosphate product immediately prior to the onset of his ulcers, led to the diagnosis of calciphylaxis. The patient was initiated on sodium thiosulfate without improvement in his lesions, and he died 3 months later after another prolonged hospitalization.

Conclusions: While calciphylaxis is a rare disease, involvement of the distal digits and especially the penis is even more uncommon and portends a particularly poor prognosis: 6-month mortality rates are reportedly as high as 70%. This suggests that prompt recognition and management of the disease is required; however, despite receiving standard therapy, our patient failed to experience improvement in his disease and instead developed several more fingertip ulcers at blood glucose sample points during his hospitalization. A corollary of the case presented here is the need for more effective management of calciphylaxis, especially for patients in whom uncommon sites, such as the penis, are involved.

Keywords: Calciphylaxis, End-stage renal disease, Hemodialysis, Penis, Sodium thiosulfate

Background

Calciphylaxis is a rare disorder of intravascular calcification that is primarily observed in patients with longstanding end-stage renal disease (ESRD). Patients develop necrotic skin ulcers covered by black “eschars” that are typically found in areas of adiposity such as the abdomen and thighs; however, distal (digits, penis) and visceral (lungs, intestines) sites can also be involved. Patients often have an elevated serum calcium-phosphate product (> 70 mg/dL) and exhibit diffuse intravascular calcification on imaging [1]. Skin biopsy may provide definitive evidence of calciphylaxis; however, diagnosis is often made clinically in patients who present with the above findings [2].

There is currently no consensus on the optimal treatment for calciphylaxis; management is guided by observational studies that advocate for a multimodal approach involving wound care, proper analgesia, infection prevention, and correction of serum calcium and phosphate levels. A trial of sodium thiosulfate (STS) is also

*Correspondence: b-jain@northwestern.edu

1 Division of Hospital Medicine at Jesse Brown VAMC, Northwestern University Feinberg School of Medicine, 820 S Damen Ave, Suite 7566, Chicago, IL 60612, USA

Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
recommended for all patients with calciphylaxis owing to its reported success in several case series; however, there is a paucity of large-scale clinical trials to support this [3]. Even with appropriate management, calciphylaxis is a lethal disease: 6-month mortality rate is estimated to be 50%, with most patients dying from overwhelming infection [4]. Involvement of the penis, as in our patient, is a particularly poor prognostic indicator, with 6-month mortality rates as high as 70% [5, 6].

Here we present the case of an elderly male with ESRD and painful necrotic ulcers of his glans penis and digits. This case depicts a distribution of calciphylaxis that is uncommon and carries an exceptionally high mortality burden; it also highlights the need for further study of this condition.

**Case presentation**

A 73-year-old African American man with a history of ESRD on hemodialysis, coronary artery disease status post-high-risk percutaneous coronary intervention requiring mechanical circulatory support 3 weeks prior, heart failure with preserved ejection fraction, hypertension, and diabetes, presented with necrotic lesions on multiple distal digits and the glans penis developing over the past 2 months. The patient denied any new exposures or trauma to the areas of ulceration and had no history of tobacco use. Of note, the lesion on his glans penis was recently treated with a 1-week course of oral amoxicillin–clavulanic acid without improvement.

The patient was afebrile and had a blood pressure of 87/52 mmHg. Physical examination revealed several small, exquisitely tender, necrotic ulcers with overlying black eschars on multiple finger pads; a gangrenous distal left third toe; and a foul-smelling lesion on the glans penis with overlying purulence (Fig. 1). The digital lesions were cool to the touch and without surrounding edema or erythema. Examination was otherwise unremarkable except for a systolic ejection murmur that was noted previously.

Laboratory results obtained during admission were notable for a blood urea nitrogen of 40 mg/dL (reference range 7–21 mg/dL), potassium 5.1 mmol/L (3.5–4.7 mmol/L), calcium 9.1 mg/dL (8.5–10.1 mg/dL), phosphorus 1.5 mg/dL (2.5–4.9 mg/dL), parathyroid hormone (PTH) 104 pg/mL (18.4–80.1 pg/mL), albumin 2.9 g/dL (3.4–5.0 g/dL), white cell count 6.8 K/μL (4.0–11.0 K/μL), hemoglobin 7.3 g/dL (13.0–17.0 g/dL), and hemoglobin A1c 6.9% (≤ 5.6%). Upon chart review, his serum calcium and phosphorus were found to be 9.2 mg/dL and 9.0 mg/dL (product = 82.8 mg/dL) when the penile lesion first appeared.

The patient underwent a computed tomography (CT) scan of the abdomen and pelvis, which revealed extensive intravascular calcification correlating with the ulcerating wound on the glans (Fig. 2). These radiographic findings, in a patient ESRD and recently elevated calcium and phosphate levels, yielded a clinical diagnosis of calciphylaxis. Treatment with thrice weekly sodium thiosulfate (25 g) during dialysis was initiated. A confirmatory skin biopsy performed later in his hospital course was inconclusive.

![Image of the patient’s penis shortly after admission. Necrosis of the glans with overlying purulence can be seen](image1)

![Computed tomography scan of the patient’s pelvis. Imaging revealed diffuse vascular calcification including the penile arteries, as shown. These radiographic lesions correlated with overlying skin necrosis](image2)
Although the patient tolerated treatment without appreciable side effects, he experienced no improvement in the digital or penile lesions; in fact, he developed several more painful, necrotic ulcers corresponding with finger-stick blood glucose sample points. He was discharged home with plans to continue regular STS during dialysis. On follow-up, his wounds remained painful but showed no further progression; unfortunately, he died 3 months later after another prolonged hospitalization.

Discussion
Calciphylaxis is a devastating disease that results from significant calcification of the tunica media of dermal arterioles and capillaries. The exact mechanism of pathogenesis is unknown, but hyperparathyroidism, hypervitaminosis D, and elevated serum calcium and phosphorus have all been implicated [7]. It is thought that calcium deposition and subsequent endothelial injury promotes formation of microthrombi, which reduces luminal caliber leading to ischemia and necrosis of overlying tissues.

Calciphylaxis is usually diagnosed in patients with dialysis-dependent ESRD; other risk factors include diabetes mellitus, autoimmune disease, malignancy, kidney transplant, and hypoaalbuminemia [7, 8]. The annual incidence in patients with ESRD is approximately 0.04–4% and thought to be increasing [1, 9]. Prevalence of calciphylaxis has been less well studied and is likely underestimated; one cross-sectional study estimated the prevalence in ESRD to be 4.1% [10]. The average age at diagnosis is between 50 and 70 years, with roughly two-thirds of patients being women [1, 11]. While calciphylaxis has been conventionally thought to develop over areas of adiposity, a 2019 meta-analysis of 856 cases found that the distal lower extremities were the most common site of involvement (55%), followed by the proximal lower extremities (40%) and then the trunk (31%) [2, 12]. Upper extremity involvement, as in our patient, was only seen in approximately 10% of all cases. Due to its rich vascular network, calciphylaxis of the penis is even less common: a 2018 review estimates that as few as 50 cases have been reported in the literature [13, 14].

Lesions in calciphylaxis may begin as indurated nodules or plaques resembling livedo reticularis, before progressing to necrotic ulcers with or without eschars [15]. However, initial presentation can vary significantly, so diagnosis requires a high degree of suspicion in the proper clinical context. Other features that may suggest presence of the disease include obesity, hyperparathyroidism, and an elevated (> 70 mg/dL) serum calcium–phosphate product in the months leading up to appearance of the lesions, as seen in our patient [16]. Further diagnostic testing is not required if the presentation is typical; however, if imaging is obtained, it may reveal intravascular or soft tissue calcification in corresponding areas [17]. Skin biopsy can provide definitive evidence of calciphylaxis, but is often reserved for ambiguous cases since it can predispose to wound complications or be nondiagnostic, as it was in this patient [18]. Importantly, some sources even argue that biopsy is contraindicated in penile calciphylaxis because of low diagnostic yield, as well as the particularly high risk of sepsis or acceleration of necrosis [19, 20].

A major challenge in management of calciphylaxis is the lack of consistent supporting evidence for a first-line treatment. Sodium thiosulfate (STS) is a drug that may possess beneficial vasodilatory and antioxidant effects and has been associated with longer survival in several case series; however, subjects in these studies were often managed with complex treatment regimens, making it difficult to assess the efficacy of STS monotherapy [2, 21]. Furthermore, a 2019 meta-analysis failed to demonstrate an improvement in wound progression or mortality from calciphylaxis through use of STS [12]. Nevertheless, a trial of this medication is recommended in all patients for at least 1 month [3].

In addition to STS, management of calciphylaxis is multifaceted and involves appropriate analgesia, wound care, infection prevention, and optimization of dialysis [22]. Abnormalities in serum calcium and phosphate should also be corrected through use of binders such as sevelamer, with a goal product of < 55 mg/dL [6]. Cinaclacet, a calcimimetic, is considered in cases of significant hyperparathyroidism (PTH > 300 pg/mL) and thus was not indicated in this patient [12]. If superimposed infection is suspected, as in our patient, empiric antibiotics with activity against methicillin-resistant Staphylococcus aureus and anaerobes should be initiated promptly given the high associated mortality risk. Despite theoretical benefits, anticoagulation does not play a major role in management; in fact, warfarin therapy has been established as a risk factor for calciphylaxis, possibly through inhibition of vitamin K-dependent regulatory proteins that prevent vascular calcification [7, 23].

Experimental therapies such as hyperbaric oxygen and pentoxifylline have been explored, with some success, in treating resistant calciphylaxis but continue to lack large-scale supporting evidence [7, 15]. Surgical management, such as revascularization procedures and partial or total penectomy, has also been described in select cases of penile calciphylaxis but does not appear to confer a survival benefit [13, 14].

Even with prompt initiation of treatment, calciphylaxis portends a dismal prognosis. The disease has a 6-month survival rate of approximately 50%, with disseminated infection continuing to account for most
declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
2 Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
3 Division of Hospital Medicine at Jesse Brown VAMC, Northwestern University Feinberg School of Medicine, 820 S Damen Ave, Suite 7566, Chicago, IL 60612, USA.

Received: 13 October 2021 Accepted: 14 December 2021
Published online: 18 January 2022

References
1. Brandenburg VM, Kramann R, Rothe H, Kaessler N, Korbiel J, Specht P, et al. Calcific uremic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol Dial Transpl. 2017;32(1):126–32.
2. Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. N Engl J Med. 2018;378(18):1704–14.
3. Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, Lacson E Jr. Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol. 2013;8(7):1162–70.
4. McCarthy JT, El-Azhary RA, Patzelt MT, Weaver AL, Albright RC, Bridges AD, et al. Survival, risk factors, and effect of treatment in 101 patients with calciphylaxis. Mayo Clin Proc. 2016;91(10):1384–94.
5. O’Neil B, Southwick AW. Three cases of penile calciphylaxis: a review of the literature. Semin Dial. 2002;15(3):172–86.
6. Sandhu G, Gini MB, Ranade A, Djebali D, Smith S. Penile calciphylaxis: a life-threatening condition successfully treated with sodium thiosulfate. Am J Ther. 2012;19(1):e66–8.
7. Nigwekar SU, Kroshinsky D, Nazarian RA, Governan J, Malhotra R, Jackson VA, et al. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. 2015;66(1):133–46.
8. Nigwekar SU, Wolf M, Sterns RH, Hix JK. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol. 2008;3(4):1139–43.
9. Nigwekar SU, Solid CA, Ankers E, Malhotra R, Eggett W, Turchin A, et al. Quantifying a rare disease in administrative data: the example of calci- phylaxis. J Gen Intern Med. 2014;29:5724–31.
10. Angelis M, Wong LL, Myers SA, Wong LM. Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery. 1997;122(6):1083–9.
11. Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Derma- tol. 2007;56(4):569–79.
12. Udomkarnjananun S, Kongnathasate K, Praditpornsilpa K, Eiam-Ong S, Jaber BL, Susantitaphong P. Treatment of calciphylaxis in CKD: a systematic review and meta-analysis. Kidney Int Rep. 2019;4(2):231–44.
13. Yang TY, Wang TY, Chen M, Sun FJ, Chiu AW, Chen YH. Penile calciphylaxis in a patient with end-stage renal disease: a case report and review of the literature. Open Med (Wars). 2018;13:158–63.
14. Karpman E, Davis S, Kurzrock EA. Penile calciphylaxis: analysis of risk factors and mortality. J Urol. 2003;169(6):2206–9.
15. Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial. 2002;15(3):172–86.
16. Ghosh T, Winchester DS, Davis MDP, El-Azhary R, Comfere NI. Early clinical presentations and progression of calciphylaxis. Int J Dermatol. 2017;56(8):856–61.
17. Halasz CL, Munger DP, Frimmer H, Dicorato M, Wainwright S. Calciphylaxis: comparison of radiologic imaging and histopathology. J Am Acad Dermatol. 2017;77(2):241-6.e3.
18. Chang JJ. Calciphylaxis: diagnosis, pathogenesis, and treatment. Adv Skin Wound Care. 2019;32(5):205–13.
19. Cimmino CB, Costabile RA. Biopsy is contraindicated in the management of penile calciphylaxis. J Sex Med. 2014;11(10):2611–7.
20. Bani-Hani M, Nawafeh S, Al-zubii M, Alkhatatbeh H, Altal Y, Sarhan MY, et al. Penile calciphylaxis diagnosis and treatment challenges a case report. Int J Surg Case Rep. 2020;77:187–90.
21. Baldwin C, Farah M, Leung M, Taylor P, Werb R, Kiaii M, et al. Multi-intervention management of calciphylaxis: a report of 7 cases. Am J Kidney Dis. 2011;58(6):988–91.
22. Harris C, Kiaii M, Lau W, Farah M. Multi-intervention management of calcific uremic arteriolopathy in 24 patients. Clin Kidney J. 2018;11(5):704–9.
23. Yu WY, Bhutani R, Kornik R, Pincus LB, Mauro T, Rosenthal MD, et al. Warfarin-associated nonuremic calciphylaxis. JAMA Dermatol. 2017;153(3):309–14.
24. Adrogué HJ, Frazier MR, Zeluff B, Suki WN. Systemic calciphylaxis revisited. Am J Nephrol. 1981;1(3–4):177–83.
25. Campbell RA, Alzweri LM, Sopko NA, Macura KJ, Burnett AL. Penile calciphylaxis: the use of radiological investigations in the management of a rare and challenging condition. Urol Case Rep. 2017;13:113–6.
26. Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. 2002;61(6):2210–7.
27. Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 2001;60(1):324–32.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.